Decrease of intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.
Hypersensitivity to the active substances, or to any of the excipients. Bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease. Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock. Severe allergic rhinitis and bronchial hyperreactivity; hypersensitivity to other beta blockers. Hyperchloremic acidosis. Severe renal impairment. Hypersensitivity to sulphonamides.
Like other topically applied ophthalmic agents, brinzolamide and timolol are absorbed systemically. Due to the beta adrenergic component, timolol, the same types of cardiovascular and pulmonary adverse reactions as seen with systemic beta adrenergic blocking agents may occur. Cardiac failure should be adequately controlled before beginning therapy with timolol. Patients with a history of severe cardiac disease should be watched for signs of cardiac failure and have their pulse rates checked. The effect on intraocular pressure or the known effects of systemic beta blockade may be potentiated when Azarga is given to patients already receiving an oral beta adrenergic blocking agent. The use of two local beta adrenergic blocking agents or two local carbonic anhydrase inhibitors is not recommended. There is limited experience in the treatment of patients with pseudoexfoliative glaucoma or pigmentary glaucoma. Caution should be utilised in treating these patients and close monitoring of IOP is recommended. The product has not been studied in patients with narrow angle glaucoma and its use is not recommended in these patients. The possible role of brinzolamide on corneal endothelial function has not been investigated in patients with compromised corneas (particularly in patients with low endothelial cell count). Specifically, patients wearing contact lenses have not been studied and careful monitoring of these patients when using brinzolamide is recommended, since carbonic anhydrase inhibitors may affect corneal hydration and wearing contact lenses might increase the risk for the cornea. Careful monitoring of patients with compromised corneas, such as patients with diabetes mellitus or corneal dystrophies, is recommended. Since the product contains benzalkonium chloride, close monitoring is required with frequent or prolonged use. Contact with soft contact lenses is to be avoided. Patients must be instructed to remove contact lenses prior to the application and wait 15 minutes after instillation of the dose before reinsertion. Pregnancy and lactation: Should not be used during pregnancy unless clearly necessary. Can be used during breast-feeding. See prescribing information for full details.
Dysgeusia, blurred vision, eye pain, eye irritation, foreign body sensation in eyes. See prescribing information for full details.
No interaction studies have been performed. See prescribing information for full details.